Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Celldex Therapeutics, Inc./ SCHEDULE 13G/A

SEC Filing · SCHEDULE 13G/A

Celldex Therapeutics, Inc.

CLDXNASDAQEQUITYCurrent

SEC Filing

Filed Aug 14, 2026Accepted Aug 14, 2026, 12:09 PM EDTCIK 744218Accession 0001907884-26-000013
View company →Permanent SEC source ↗
Share

Company context

Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.

Current securities

CLDXNASDAQ · EQUITY · Current

Recent company filings

  1. Other EventsSep 22, 2026
  2. 10-Q filingAug 6, 2026
  3. Results of Operations and Financial ConditionAug 6, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 15, 2026
  5. 4 filingJun 29, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗